To Study the Effect of Ayurvedic Compound in Patient of Tamaka Shwasa (Bronchial Asthma)â??

â??Pre-Clinical & Clinical Evaluation of Anti-asthmatic and Anti-inflammatory Activity of a Herbo-mineral Ayurvedic Compound in Tamaka Shwasa (Bronchial Asthma)â??

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052956

Enrollment

Registered

2023-05-19

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: PCS-

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients in the age group of 18-60 yrs. 2.Patients with Intermittent, mild-persistent & moderate-persistent asthma according to GINA classification and are not on regular medication for Asthma. 3.Patients having symptoms of Nasal allergies like sneezing, nasal discharge and having raised eosinophil count with or without chest symptoms cough, wheezing. 4.Patients having FEV1 > 60% of predicted value. 5.Patients who have not received any AYUSH intervention in last 15 days for related symptoms.

Exclusion criteria

Exclusion criteria: 1.Patients having Acute exacerbation of asthma. 2.Patients having FEV1 3.Diagnosed cases of tuberculosis, pneumonia, COPD and other acute and chronic pulmonary disorders. 4.K/c/o malignancies of the respiratory and other system. 5.Patients who have consumed AYUSH intervention for related complaints in last 15 days. 6.Patients on regular anti allergic medications. 7.Patients on immunotherapy for allergy. 8.Patients with Haemoglobin less than 9 gm/dl. 9.Patients having concomitant systemic illness like uncontrolled Hypertension, Poorly controlled Diabetes Mellitus, Renal failure, Malignancy, Acute or Chronic liver disease.

Design outcomes

Primary

Measure	Time frame
Changes in Peak expiratory flow rate(PEFR)from baseline value at the end of 4 week.Timepoint: 0, 2 Week, 4 Week	—

Secondary

Measure	Time frame
ï?¼Changes in Absolute Eosinophil count from baseline values at the end of 4th week. ï?¼Changes in Asthma control questionnaire (ACQ) score from baseline value at the end of 4th week. ï?¼Changes in Nasal symptom score (if present) from baseline value at the end of 4th week. ï?¼ Average reduction in night time symptoms from baseline value at the end of 4th week. Timepoint: 0,2 Week & 4 Week	—

Measure

Time frame

ï?¼Changes in Absolute Eosinophil count from baseline values at the end of 4th week. ï?¼Changes in Asthma control questionnaire (ACQ) score from baseline value at the end of 4th week. ï?¼Changes in Nasal symptom score (if present) from baseline value at the end of 4th week. ï?¼ Average reduction in night time symptoms from baseline value at the end of 4th week. Timepoint: 0,2 Week & 4 Week

—

Countries

India

Contacts

Public ContactDr Jasmin Banu

National Institute of Ayurveda,Deemed to be University, Jaipur

dr.abhishek82@gmail.com9915613039

Outcome results